Influenza vaccination in the elderly
- 6 July 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 14 (3), 540-549
- https://doi.org/10.1080/21645515.2017.1343226
Abstract
Seasonal influenza is a prevalent and serious annual illness resulting in widespread morbidity and economic disruption throughout the population; the elderly and immunocompromised are particularly vulnerable to serious sequelae and mortality. The changing demographics worldwide to an aging society have important implications for public health policy and pharmaceutical innovations. For instance, primary prevention via immunization is effective in reducing the burden of influenza illness among the elderly. However, the elderly may be insufficiently protected by vaccination due to the immunosenescence which accompanies aging. In addition, vaccine hesitancy among the younger populations increases the likelihood of circulating infectious diseases, and thus concomitant exposure. While it is clear that the development of more immunogenic vaccines is an imperative and worthy endeavor, clinical trials continue to demonstrate that the current influenza vaccine formulation remains highly effective in reducing morbidity and mortality when well matched to circulating strains.This publication has 96 references indexed in Scilit:
- AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialThe Lancet Infectious Diseases, 2013
- Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccineVaccine, 2011
- Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1Clinical Infectious Diseases, 2011
- Key role of T cell defects in age-related vulnerability to West Nile virusThe Journal of Experimental Medicine, 2009
- Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and OlderThe Journal of Infectious Diseases, 2009
- Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled TrialThe Journal of Infectious Diseases, 2008
- Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adultsVaccine, 2008
- Biology of Immune Responses to Vaccines in Elderly PersonsClinical Infectious Diseases, 2008
- Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virusThe Journal of Experimental Medicine, 2008
- Broken Limits to Life ExpectancyScience, 2002